Yanling Jin

Publication Activity (10 Years)

Years Active: 2023-2023
Publications (10 Years): 5

Top Topics

Ejection Fraction

Chemotherapy Induced

Endoplasmic Reticulum Stress

End Stage Renal Disease

Top Venues

Cancer research communications

This page only lists publications with an associated author ORCID identifier.

Publications

Jing Wang, Xiaobo Cheng, Yanling Jin, Bili Xia, Ran Qin, Wei Zhang, Huiliang Hu, Xiaoting Mao, Liting Zhou, Jia Yan, Xiaoyan Zhang, Jianqing Xu
Safety and Clinical Response to Combined Immunotherapy with Autologous iNKT Cells and PD-1 + CD8 + T Cells in Patients Failing First-line Chemotherapy in Stage IV Pancreatic Cancer. Cancer research communications 3 (6) (2023)
Jing Wang, Xiaobo Cheng, Yanling Jin, Bili Xia, Ran Qin, Wei Zhang, Huiliang Hu, Xiaoting Mao, Liting Zhou, Jia Yan, Xiaoyan Zhang, Jianqing Xu
Safety and Clinical Response to Combined Immunotherapy with Autologous iNKT Cells and PD-1 + CD8 + T Cells in Patients Failing First-line Chemotherapy in Stage IV Pancreatic Cancer. Cancer research communications 3 (6) (2023)
Jing Wang, Xiaobo Cheng, Yanling Jin, Bili Xia, Ran Qin, Wei Zhang, Huiliang Hu, Xiaoting Mao, Liting Zhou, Jia Yan, Xiaoyan Zhang, Jianqing Xu
Safety and Clinical Response to Combined Immunotherapy with Autologous iNKT Cells and PD-1 + CD8 + T Cells in Patients Failing First-line Chemotherapy in Stage IV Pancreatic Cancer. Cancer research communications 3 (6) (2023)
Jing Wang, Xiaobo Cheng, Yanling Jin, Bili Xia, Ran Qin, Wei Zhang, Huiliang Hu, Xiaoting Mao, Liting Zhou, Jia Yan, Xiaoyan Zhang, Jianqing Xu
Safety and Clinical Response to Combined Immunotherapy with Autologous iNKT Cells and PD-1 + CD8 + T Cells in Patients Failing First-line Chemotherapy in Stage IV Pancreatic Cancer. Cancer research communications 3 (6) (2023)
Jing Wang, Xiaobo Cheng, Yanling Jin, Bili Xia, Ran Qin, Wei Zhang, Huiliang Hu, Xiaoting Mao, Liting Zhou, Jia Yan, Xiaoyan Zhang, Jianqing Xu
Safety and Clinical Response to Combined Immunotherapy with Autologous iNKT Cells and PD-1 + CD8 + T Cells in Patients Failing First-line Chemotherapy in Stage IV Pancreatic Cancer. Cancer research communications 3 (6) (2023)